Urogen Pharma (URGN) Stock Forecast & Price Target

Compare

618 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

URGN Analyst Ratings

Strong Buy

7 Buy

2 Hold

0 Sell

Based on 9 analysts giving stock ratings to

Urogen

Pharma

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

URGN Stock 12 Month Forecast

Average Price Target

$31.11

▲(57.28% Upside)

Based on 9 Wall Street analysts offering 12 month price targets for Urogen Pharma in the last 3 months. The average price target is $31.11 with a high forecast of $47.00 and a low forecast of $16.00. The average price target represents a 57.28% change from the last price of $19.78.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"3":"$3","48":"$48","14.25":"$14.25","25.5":"$25.5","36.75":"$36.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":47,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$47.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":31.11,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$31.11</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":16,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$16.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[3,14.25,25.5,36.75,48],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,19.4,21.52307692307692,23.646153846153844,25.769230769230766,27.89230769230769,30.015384615384612,32.13846153846154,34.261538461538464,36.38461538461539,38.50769230769231,40.63076923076923,42.753846153846155,44.87692307692308,{"y":47,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,19.4,20.30076923076923,21.201538461538462,22.10230769230769,23.00307692307692,23.903846153846153,24.804615384615385,25.705384615384617,26.606153846153845,27.506923076923076,28.407692307692308,29.308461538461536,30.20923076923077,{"y":31.11,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,19.4,19.138461538461538,18.876923076923077,18.615384615384613,18.353846153846153,18.092307692307692,17.83076923076923,17.569230769230767,17.307692307692307,17.046153846153846,16.784615384615385,16.52307692307692,16.26153846153846,{"y":16,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":15.82,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.91,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.48,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.2,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.88,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.65,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.01,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.46,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.63,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.41,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.84,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.02,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.4,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$47.00

Average Price Target$31.11

Lowest Price Target$16.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Kelsey Goodwin

Piper Sandler

$36

Buy

82.00%

Upside

Initiated

08/19/25

UroGen Pharma initiated with an Overweight at Piper SandlerUroGen Pharma initiated with an Overweight at Piper Sandler

Tara Bancroft

TD Cowen

$35

Buy

76.95%

Upside

Reiterated

08/14/25

Urogen Pharma (URGN) Receives a Buy from TD Cowen

Dex Genotek

TR | OpenAI - 4o

$18

Hold

-9.00%

Downside

Reiterated

08/14/25

AI Generated ArticleAI Generated Article

Ram Selvaraju

H.C. Wainwright

$50→$40

Buy

102.22%

Upside

Reiterated

08/11/25

UroGen Pharma price target lowered to $40 from $50 at H.C. WainwrightUroGen Pharma price target lowered to $40 from $50 at H.C. Wainwright

Leland Gershell

Oppenheimer

$31

Buy

56.72%

Upside

Reiterated

08/08/25

Urogen Pharma (URGN) Gets a Buy from Oppenheimer

Michael Schmidt

Guggenheim

$30→$32

Buy

61.78%

Upside

Reiterated

08/07/25

Wall Street Analysts Are Bullish on Top Healthcare PicksOur PT moves to $32 (from $30) and we maintain our Buy rating on URGN.

George Farmer

Scotiabank

$47

Buy

137.61%

Upside

Reiterated

08/06/25

Scotiabank Reaffirms Their Buy Rating on Urogen Pharma (URGN)

Paul Choi

Goldman Sachs

$3→$16

Hold

-19.11%

Downside

Reiterated

06/13/25

UroGen Pharma price target raised to $16 from $3 at Goldman SachsUroGen Pharma price target raised to $16 from $3 at Goldman Sachs

Jason Kolbert

D. Boral Capital

$25

Buy

26.39%

Upside

Reiterated

06/12/25

UroGen's Zusduri approval validates FDA's flexibility, says D. BoralUroGen's Zusduri approval validates FDA's flexibility, says D. Boral

John Ransom

Raymond James

$40→$36

Buy

82.00%

Upside

Reiterated

03/11/25

UroGen Pharma (URGN) PT Lowered to $36 at Raymond JamesRaymond James analyst Reni Benjamin lowered the price target on UroGen Pharma (NASDAQ: URGN) to $36.00 (from $40.00) while maintaining a Outperform rating.

Aydin Huseynov

Ladenburg Thalmann & Co.

$31

Buy

56.72%

Upside

Reiterated

02/19/25

UroGen Pharma transferred with Buy rating at LadenburgUroGen Pharma transferred with Buy rating at Ladenburg

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Kelsey Goodwin

Piper Sandler

$36

Buy

82.00%

Upside

Initiated

08/19/25

UroGen Pharma initiated with an Overweight at Piper SandlerUroGen Pharma initiated with an Overweight at Piper Sandler

Tara Bancroft

TD Cowen

$35

Buy

76.95%

Upside

Reiterated

08/14/25

Urogen Pharma (URGN) Receives a Buy from TD Cowen

Dex Genotek

TR | OpenAI - 4o

$18

Hold

-9.00%

Downside

Reiterated

08/14/25

AI Generated ArticleAI Generated Article

Ram Selvaraju

H.C. Wainwright

$50→$40

Buy

102.22%

Upside

Reiterated

08/11/25

UroGen Pharma price target lowered to $40 from $50 at H.C. WainwrightUroGen Pharma price target lowered to $40 from $50 at H.C. Wainwright

Leland Gershell

Oppenheimer

$31

Buy

56.72%

Upside

Reiterated

08/08/25

Urogen Pharma (URGN) Gets a Buy from Oppenheimer

Michael Schmidt

Guggenheim

$30→$32

Buy

61.78%

Upside

Reiterated

08/07/25

Wall Street Analysts Are Bullish on Top Healthcare PicksOur PT moves to $32 (from $30) and we maintain our Buy rating on URGN.

George Farmer

Scotiabank

$47

Buy

137.61%

Upside

Reiterated

08/06/25

Scotiabank Reaffirms Their Buy Rating on Urogen Pharma (URGN)

Paul Choi

Goldman Sachs

$3→$16

Hold

-19.11%

Downside

Reiterated

06/13/25

UroGen Pharma price target raised to $16 from $3 at Goldman SachsUroGen Pharma price target raised to $16 from $3 at Goldman Sachs

Jason Kolbert

D. Boral Capital

$25

Buy

26.39%

Upside

Reiterated

06/12/25

UroGen's Zusduri approval validates FDA's flexibility, says D. BoralUroGen's Zusduri approval validates FDA's flexibility, says D. Boral

John Ransom

Raymond James

$40→$36

Buy

82.00%

Upside

Reiterated

03/11/25

Aydin Huseynov

Ladenburg Thalmann & Co.

$31

Buy

56.72%

Upside

Reiterated

02/19/25

UroGen Pharma transferred with Buy rating at LadenburgUroGen Pharma transferred with Buy rating at Ladenburg

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Urogen Pharma

1 Month

xxx

Success Rate

13/25 ratings generated profit

Average Return

+16.47%

reiterated a xxx

rating 15 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 52.00% of your transactions generating a profit, with an average return of +16.47% per trade.

3 Months

xxx

Success Rate

14/25 ratings generated profit

Average Return

+25.88%

reiterated a xxx

rating 15 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 56.00% of your transactions generating a profit, with an average return of +25.88% per trade.

1 Year

Tara BancroftTD Cowen

Success Rate

8/11 ratings generated profit

Average Return

+25.39%

reiterated a buy rating 9 days ago

Copying Tara Bancroft's trades and holding each position for 1 Year would result in 72.73% of your transactions generating a profit, with an average return of +25.39% per trade.

2 Years

xxx

Success Rate

11/11 ratings generated profit

Average Return

+40.27%

reiterated a xxx

rating 9 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +40.27% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

URGN Analyst Recommendation Trends

Rating

Apr 25

May 25

Jun 25

Jul 25

Aug 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, URGN has received 21 Buy Ratings, 11 Hold Ratings, and 0 Sell Ratings. URGN average Analyst price target in the past 3 months is 31.11.

Each month's total comprises the sum of three months' worth of ratings.

URGN Financial Forecast

URGN Earnings Forecast

Next quarter’s earnings estimate for URGN is -$0.64 with a range of -$0.76 to -$0.45. The previous quarter’s EPS was -$1.05. URGN beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.05% of the time in the same period. In the last calendar year URGN has Outperformed its overall industry.

URGN Sales Forecast

Next quarter’s sales forecast for URGN is $34.66M with a range of $28.60M to $42.12M. The previous quarter’s sales results were $24.21M. URGN beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 46.86% of the time in the same period. In the last calendar year URGN has Outperformed its overall industry.

URGN Stock Forecast FAQ

What is URGN’s average 12-month price target, according to analysts?

Based on analyst ratings, Urogen Pharma’s 12-month average price target is 31.11.

What is URGN’s upside potential, based on the analysts’ average price target?

Urogen Pharma has 57.28% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is URGN a Buy, Sell or Hold?

Urogen Pharma has a consensus rating of Strong Buy which is based on 7 buy ratings, 2 hold ratings and 0 sell ratings.

What is Urogen Pharma’s price target?

The average price target for Urogen Pharma is 31.11. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $47.00 ,the lowest forecast is $16.00. The average price target represents 57.28% Increase from the current price of $19.78.

What do analysts say about Urogen Pharma?

Urogen Pharma’s analyst rating consensus is a Strong Buy. This is based on the ratings of 9 Wall Streets Analysts.

How can I buy shares of URGN?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Urogen Pharma (URGN) Stock Forecast & Price Target

URGN Analyst Ratings

URGN Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Urogen Pharma

URGN Analyst Recommendation Trends

URGN Financial Forecast

URGN Earnings Forecast

URGN Sales Forecast

URGN Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts